Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192880 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 625
- Enrollment target
NCT01192880 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 625 participants.
The verdict
NCT01192880, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 625 participants
- Enrollment target
Study Summary
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of schizophrenia. Participants, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.
Interventions
- DRUG Placebo
- DRUG Antipsychotics
- DRUG Bitopertin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 625 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01192880
The ClinicalTrials.gov registry entry for NCT01192880 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 625 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01192880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01192880 about?
NCT01192880 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia". This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of schizophrenia. Participants, on stable treatment with antipsychotics, will ...
What is the current status of trial NCT01192880?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 625 participants. The study started on 2010-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01192880?
The interventions under investigation include: Placebo (DRUG), Antipsychotics (DRUG), Bitopertin (DRUG).
Who is sponsoring clinical trial NCT01192880?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.